Yes / Background: Group B Streptococcus (GBS) is a leading cause of morbidity and mortality in infants in both
developed and developing countries. To our knowledge, only a few studies have been reported the clinical
features, treatment and outcomes of the GBS disease in China. The severity of neonatal GBS disease in China
remains unclear. Population-based surveillance in China is therefore required.
Methods: We retrospectively collected data of <3 months old infants with culture-positive GBS in sterile samples
from three large urban tertiary hospitals in South China from Jan 2011 to Dec 2014. The GBS isolates and their
antibiotic susceptibility were routinely identified in clinical laboratories in participating hospitals. Serotyping and
multi-locus sequence typing (MLST) were also conducted for further analysis of the neonatal GBS disease.
Results: Total 70 cases of culture-confirmed invasive GBS infection were identified from 127,206 live births born in
studying hospitals, giving an overall incidence of 0.55 per 1000 live births (95% confidence interval [CI] 0.44–0.69).
They consisted of 49 with early-onset disease (EOD, 0.39 per 1000 live births (95% CI 0.29–0.51)) and 21 with
late-onset disease (LOD, 0.17 per 1000 live births (95% CI 0.11–0.25)). The incidence of EOD increased significantly over
the studying period. Five infants (4 EOD and 1 LOD) died before discharge giving a mortality rate of 7.1% and five
infants (7.1%, 2 EOD and 3 LOD) had neurological sequelae. Within 68 GBS isolates from GBS cases who born in the
studying hospitals or elsewhere, serotype III accounted for 77.9%, followed by Ib (14.7%), V (4.4%), and Ia (2.9%). MLST
analysis revealed the presence of 13 different sequence types among the 68 GBS isolates and ST-17 was the most
frequent sequence type (63.2%). All isolates were susceptible to penicillin, ceftriaxone, vancomycin and linezolid, while
57.4% and 51.5% were resistant to erythromycin and clindamycin, respectively.
Conclusions: This study gains the insight into the spectrum of GBS infection in south China which will facilitate the
development of the guidance for reasonable antibiotics usage and will provide evidence for the implementation of
potential GBS vaccines in the future. / Supported by medical and health science and technology projects of Health and Family Planning Commission of Guangzhou Municipality (grant number 20151A010034) and Guangdong provincial science and technology planning projects (grant number 2014A020212520).
| Identifer | oai:union.ndltd.org:BRADFORD/oai:bradscholars.brad.ac.uk:10454/15101 |
| Date | 08 January 2018 |
| Creators | Guan, X., Mu, X., Ji, W., Yuan, C., He, P., Zhang, L., Huang, Y., Li, J., Chen, J., Zhong, H., Pang, S., Tan, N., Deng, Q., Gao, K., Huang, Y., Chang, Chien-Yi, Liu, H. |
| Source Sets | Bradford Scholars |
| Language | English |
| Detected Language | English |
| Type | Article, Published version |
| Rights | © The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
Page generated in 0.0018 seconds